Syngene Intl joins global consortium of healthcare groups on Covid testing

Syngene International Ltd on Thursday said it has joined a global consortium of 19 organisations from the healthcare industry to help inform, improve and accelerate various aspects of COVID-19 testing.

The consortium, led by Bristol Myers Squibb, will focus on a wide range of aspects from research to clinical diagnostic applications, the company said in a statement.

A diverse group of companies with synergistic areas of expertise, including precision medicine, diagnostics, occupational health, pharmaceuticals and clinical testing laboratories, the consortium will help provide clarity and potential solutions to COVID-19 testing challenges, it added.

To advance the common goal, the members canshare relevant expertise, materials and experiences to accelerate understanding of COVID-19.

Moreover, they can analyse available scientific and health data, materials and information to develop, improve and deploy current assays and new approaches for the COVID-19 testing paradigm, the company said.

Syngene COO Mahesh Bhalgat said, "Bristol Myers Squibb and Syngene have been research partners for fifteen years. We fully support the aims of the consortium and look forward to sharing our experience and expertise of the past six months, and are operating one of the largest RT-PCR testing private laboratories in Karnataka."

He added that the world of medical science is benefitting enormously by sharing information about this coronavirus and we welcome the opportunity to contribute.

Through the consortium, members may also contribute knowledge gained from the collaborative research by publishing work that will inform the scientific community and general public of the consortium's findings, the statement added.

Syngene said since the outbreak of the coronavirus pandemic, it has been actively contributing its scientific expertise and resources in the fight against the virus.

It has collaborated with the Centre for Cellular and Molecular Biology (CCMB) to deliver a high throughput next generation sequencing (NGS)-based genomic screening assay that can test 5,000-10,000 samples simultaneously, thecompany said.

Besides, Syngene's RT-PCR testing centre has conducted more than 50,000 tests and has tied up with over 50 organisations for testing their employees, the company added.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel